Snapshot
TransMedics Group, Inc. reported $157M of revenue in Q2 2025, up 37.7% year over year, with diluted EPS of $0.92 and an operating margin of 23.2%.
- Revenue
- $157M
- YoY growth
- +37.7%
- Diluted EPS
- $0.92
- Operating margin
- 23.2%
What management said
- •Transplant system to enable greater utilization of donor organs to meet the growing demand for more and better organ transplantation.
- •But first, let me highlight our 2Q performance, which represents a new high watermark for both clinical cases and revenue.
- •Our performance has also demonstrated a significant operating leverage potential of the TransMedics business, even as we continue to invest across several growth initiatives.
- •We are already ramping up our investments to drive the next several waves of growth that would deliver substantially more top and bottom line growth for TransMedics.
- •Total revenue for 2Q twenty twenty five was $157,400,000 representing approximately 38% growth year over year and approximately 10% sequential growth from 1Q twenty twenty five.
- •We experienced sequential growth across all three organ segments driven by higher overall utilization and center penetration of OCS NOP in The U.
- •Our overall gross margin for 2Q was steady at 61.4% similar to Q1.
- •Meanwhile, we delivered operating profit of approximately $36,600,000 in 2Q, representing more than 23% of total revenue and up from $27,400,000 or 19% of total revenue in 1Q twenty twenty five.
- •We hope these results cement our commitment to profitable growth and cash generation.
- •In fact, our pipeline strategy of adding the OCS kidney platform is designed to position us to achieve at least over 20,000 annual U.
- •Strong transplant volume growth combined with the positive impact of our ongoing strategic investments drove solid performance across both product and service lines, along with continued margin expansion and improved profitability.
- •Transplant revenue was approximately $152,000,000 up 40% year over year and 10% sequentially.
What went well
- •Q2 2025 total revenue was $157.4 million, representing approximately 38% growth year-over-year and approximately 10% sequential growth, described as a new high watermark for both clinical cases and revenue.
- •The company achieved sequential growth across all three organ segments, with OCS Lung experiencing approximately 14% sequential growth, dispelling outside commentary on lung transplantation.
- •Operating profit was approximately $36.6 million, more than 23% of total revenue, up from $27.4 million (19%) in Q1 2025, with operating margin expanding to 23% from 11% a year earlier.
- •Gross margin was steady at approximately 61.4%, similar to Q1, with service margin up 431 basis points year-over-year on higher fleet utilization and logistics efficiencies.
- •Strong cash generation added approximately $90 million to the balance sheet, ending Q2 with over $401 million in cash, supported by an improved billing cycle and healthy AR collections.
What went wrong
- •OUS/international revenue was approximately $4 million, down 12% from 2024 (up only 2% sequentially), reflecting the early-stage nature and variability of the international business.
- •Product margin was flat versus 2024 and declined 172 basis points sequentially, largely due to higher freight expenses from a deliberate action to accelerate inventory replenishment to hubs.
- •Management cautioned that gross margin improvement would moderate in the second half as scheduled aviation fleet maintenance ramps up in Q3 and becomes more pronounced in Q4.
- •The U.S. heart market itself has been relatively flat over the last six to eight quarters, with Q1 growth reversing in Q2, attributed to ebbs and flows of wait list replenishment and DCD non-progression.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Full-year revenue | FY2025 | $565M-$585M | raised to $585M-$605M, approximately 35% growth over 2024 at the midpoint | |
| Gross margin | Coming years | approximately 60% | approximately 60% | |
| Operating margin expansion vs prior year | FY2025 | — | at least 650 basis points increase, driven mainly by operating leverage on operating expenses, with potential upside | |
| Operating margin target | FY2028 | — | at or approaching 30% operating margin, path may not be linear | |
| Clinical trial revenue contribution | FY2025 | 2%-5% (stated at December Investor Day) | no substantial growth assumed from clinical trials in 2025; enough organic growth to meet guidance |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Total revenue | approximately +38% | Higher overall utilization and center penetration of OCS NOP in the U.S. across all three organ segments, a new high watermark for case volume. |
| U.S. transplant revenue | +40% | Increasing organ utilization in liver ($116M) and OCS adoption across liver and heart ($32M), plus lung ($4M). |
| Service revenue | +44% | Primarily logistics revenue, which grew 56% year-over-year and 14% sequentially on continued aviation fleet expansion and utilization. |
| Operating income | +192% | Strong transplant volume growth and operating leverage, with operating expenses up only 6% year-over-year against revenue up approximately 38%. |
| Net income | +186% | Strong operating performance; EPS of $1.03 and diluted EPS of $0.92. |
| Gross margin | +78 bps to ~61.4% | A 431 basis point improvement in service margin from higher fleet utilization and logistics cost efficiencies, with product margin flat versus 2024. |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Next-gen OCS ENHANCE Heart and DENOVO Lung trials | — | Lung IDE approved with clinical trial design untouched (remaining questions focused on preclinical testing); both trials expected to start before year-end, both arms using NOP service for blinding, with full design to be posted on clinicaltrials.gov in late August/early September. | |
| U.S. transplant system modernization | — | Federal agencies and Congress driving a national initiative to modernize the U.S. transplant system; management sees no headwinds, expects some misunderstanding from OPO stakeholders, and is over-communicating that its goal is collaboration, not replacement. | |
| DCD donation and New York Times expose | — | No hesitation, concern, or pullback seen in DCD donation; management said the incidents were known in the field for about two years and were sensationalized; DCD utilization unchanged at 50%-55%. | |
| Competition (Organox) | — | Organox's in-flight approval is viewed as unwarranted noise; management said the device is designed for a back-to-base model, is too large and lacks battery capability to fly, and does not change competitive dynamics. | |
| 10,000 transplant target and OCS Kidney | — | Laser-focused on achieving and surpassing 10,000 U.S. NOP transplants in 2028, with the OCS Kidney platform positioning the company for at least over 20,000 annual U.S. transplants in subsequent years. |
Q&A summary
Allen Gong (JPMorgan) asked about July seasonality trends and whether greater OPO/DCD oversight could reduce procedures and hurt TransMedics.
Waleed Hassanein said July shows some seasonality, slightly less than last year but early. On oversight, he said it could benefit the market, citing haphazardly implemented NRP that cost dollars and lost organs, and reiterated confidence in operating under current or future systems.
Chris Pasquale (Nephron Research) asked whether the lung trial design changed with FDA and what is holding back the relatively flat U.S. heart market.
Waleed Hassanein said the clinical trial design is untouched, with remaining questions focused on preclinical testing. On heart, he attributed flatness to ebbs and flows of wait list replenishment and DCD non-progression, expecting the market to normalize by Q4 and the next-gen heart program to change the dynamic in 2026.
Matthew Mardula (William Blair) asked how next-gen OCS will help penetrate lung transplants and about future growth.
Waleed Hassanein said the next-gen lung platform addresses historical concerns (edema, post-transplant function, hesitation, ice-overnight perception), reduces edema significantly, maintains lungs beyond 24 hours, and is being compared to cold storage to deliver level one evidence of superiority and become the next standard of care.
Samantha Munoz (Piper Sandler) asked about field concerns on DCD donations post-NYT article, DCD utilization room to grow, and whether the cold storage trial arm generates revenue.
Waleed Hassanein said no pullback on DCD donation; utilization is unchanged at 50%-55% with 45%-50% not progressing. He said both trial arms use NOP for blinding, expects some logistics revenue from the control arm, but is waiving service fees on non-TransMedics technologies as good faith.
Suraj Kalia (Oppenheimer) asked to reconcile the prior 2%-5% clinical trial growth figure with the statement of no expected 2025 contribution despite raising guidance.
Waleed Hassanein clarified the 2%-5% came from the December Investor Day; given trial initiation timing, the company does not assume any substantial growth from clinical trials in 2025, and has enough organic growth to meet the raised guidance, with potential upside.
Mike Matson (Needham) asked whether trial-enrolled heart/lung patients cannibalize existing OCS volume, and about Organox's in-flight approval.
Waleed Hassanein said the trials are additive, not cannibalizing, citing roughly 300 lung patients (of 450) and around 300-350 DBD hearts the company lacks indication for today. On Organox, he said the device is designed for back-to-base, is too large to fly, and lacks battery capability, viewing it as unwarranted noise.